Inspira Technologies Terminates Financing Facilities to Focus on Next Strategic Phase

Inspira Technologies has terminated its ATM and SEPA equity facilities to prepare for its next strategic phase. The decision reflects the company's commitment to maintaining a disciplined capital structure. The company's FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira is also advancing HYLA, a proprietary blood sensor platform offering continuous, non-invasive monitoring.